9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)

Inventors

Tzanis, Evangelos L. • McGovern, Paul • Manley, Amy L. • Garrity-Ryan, Lynne • Tanaka, S. Ken

Assignees

Paratek Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10383884-B2

Patent

Publication Date

2019-08-20

Expiration Date


Abstract

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

Core Innovation

The disclosure relates to methods of treating Community-Acquired Bacterial Pneumonia (CABP) with 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof. Disclosed treatments utilize staged intravenous administration regimens, which optionally incorporate oral administration as a step-down option. The claim scope distinguishes regimens that require oral dosing from regimens providing intravenous administration without an oral dosing stage.

Clinical evaluation reports non-inferiority to moxifloxacin for early CABP response and post-treatment clinical success across stated populations. Disclosed findings further indicate sustained pulmonary exposure in epithelial lining fluid and alveolar cells, with exposure increasing less than dose-proportionally. Evaluated oral doses are reported to be generally tolerated, while problem descriptions in the background section are not explicitly described in patent.

Claims Coverage

The claim coverage encompasses three inventive features directed to staged administration regimens for treating Community-Acquired Bacterial Pneumonia using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof.

Intravenous treatment with optional oral dosing

Covers three initial intravenous doses of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, followed by one or more further intravenous doses, and optionally followed by oral dosing.

Intravenous treatment followed by oral dosing

Covers three initial intravenous doses of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, followed by one or more further intravenous doses and then one or more oral doses.

Intravenous-only treatment

Covers three initial intravenous doses of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof followed by one or more further intravenous doses, without reciting an oral dosing stage.

Together, the inventive features establish staged administration protocols for CABP treatment that differentiate between optional oral step-down dosing, mandatory oral step-down dosing, and intravenous-only therapy.

Stated Advantages

Demonstrated non-inferiority to moxifloxacin for early CABP response and post-treatment clinical success in stated populations.

Sustained pulmonary exposure, including confirmed drug levels in epithelial lining fluid and alveolar cells, with exposure increasing less than dose-proportionally.

Studied oral doses of the therapeutic compound are generally tolerated.

Documented Applications

Treatment of Community-Acquired Bacterial Pneumonia (CABP) in a subject in need of treatment, including cases associated with typical, atypical, and antibiotic-resistant pathogens.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.